Results 71 to 80 of about 251,532 (186)
Update on the use of etanercept across a spectrum of rheumatoid disorders
Bernard CombeService d’Immuno-Rhumatologie, Montpellier, FranceAbstract: Etanercept is a soluble TNF receptor p75 fusion protein which is approved for subcutaneous use (50 mg weekly) in the treatment of patients with active rheumatoid arthritis
Bernard Combe
doaj
THE EXPERIENCE OF ADALIMUMAB USE IN A PATIENT WITH PAUTSIARTICULAR JUVENILE ARTHRITIS AND UVEITIS
The article presents the observation of early debut and the severe course of the juvenile polyarthritis involving the eyes, refractory to treatment by classical immunosuppressants. Successful use of the genetically engineered biological drug — adalimumab
E.I. Alexeeva +10 more
doaj +2 more sources
Immunoglobulin E-rheumatoid factor in juvenile rheumatoid arthritis [PDF]
Rosa Aparecida Ferreira +6 more
openalex +1 more source
THU0076 Disease-modifying treatment regimens have been insufficient to reduce the incidence of systemic aa amyloidosis associated with rheumatoid arthritis in contrast to a significant reduction in those with juvenile idiopathic arthritis [PDF]
TA-B Youngstein +14 more
openalex +1 more source
Sleep Disturbances In Juvenile Rheumatoid Arthritis (JRA) 1978 [PDF]
Bradley J. Bloom +2 more
openalex +1 more source
Rheological disorders in juvenile rheumatoid arthritis and rheumatoid arthritis in adults
openalex +2 more sources
Serum Antigammaglobulins in Juvenile Rheumatoid Arthritis [PDF]
R Bardfeld +2 more
openalex +1 more source
We review the abnormal bone turnover that is the basis of idiopathic inflammatory or rheumatoid arthritis and bone loss, with emphasis on Tumor Necrosis Factor-alpha (TNFα)-related mechanisms.
Harry C Blair +8 more
doaj +1 more source

